SNDX vs. EWTX, NAMS, AMRX, GLPG, AMPH, AGIO, GPCR, DCPH, KROS, and EVO
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Edgewise Therapeutics (EWTX), NewAmsterdam Pharma (NAMS), Amneal Pharmaceuticals (AMRX), Galapagos (GLPG), Amphastar Pharmaceuticals (AMPH), Agios Pharmaceuticals (AGIO), Structure Therapeutics (GPCR), Deciphera Pharmaceuticals (DCPH), Keros Therapeutics (KROS), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
Edgewise Therapeutics (NASDAQ:EWTX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
In the previous week, Edgewise Therapeutics had 8 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for Edgewise Therapeutics and 6 mentions for Syndax Pharmaceuticals. Edgewise Therapeutics' average media sentiment score of 0.43 beat Syndax Pharmaceuticals' score of 0.07 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
Syndax Pharmaceuticals' return on equity of -32.06% beat Edgewise Therapeutics' return on equity.
Edgewise Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals received 344 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 64.54% of users gave Syndax Pharmaceuticals an outperform vote while only 62.50% of users gave Edgewise Therapeutics an outperform vote.
Edgewise Therapeutics currently has a consensus price target of $31.20, indicating a potential upside of 49.35%. Syndax Pharmaceuticals has a consensus price target of $34.42, indicating a potential upside of 53.78%. Given Edgewise Therapeutics' higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Edgewise Therapeutics.
Edgewise Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Summary
Syndax Pharmaceuticals beats Edgewise Therapeutics on 8 of the 14 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
